Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 4/20 | 0.46 |
| ▸ | CA1 known ✓ | P00915 | 4/20 | 0.46 |
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.46 |
| ▸ | P2RY4 known ✓ | P51582 | 6/20 | 0.43 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.43 |
| ▸ | P2RY12 known ✓ | Q9H244 | 6/20 | 0.43 |
| ▸ | P2RY2 known ✓ | P41231 | 5/20 | 0.43 |
| ▸ | P2RY6 known ✓ | Q15077 | 3/20 | 0.43 |
| ▸ | P2RY1 known ✓ | P47900 | 2/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498238 | 1.00 | RAD51 (0.54) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL21747691 | 1.00 | RAD51 (0.54) | RAD51CA12CA1CA2CA9 | |
| Potassium Ion SCHEMBL2219778 | 0.98 | RAD51 (0.51) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL29737199 | 0.94 | RAD51 (0.60) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL30532269 | 0.94 | RAD51 (0.60) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL893765 | 0.94 | RAD51 (0.60) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL1169584 | 0.94 | RAD51 (0.60) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL2221675 | 0.91 | RAD51 (0.46) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL4821301 | 0.89 | RAD51 (0.55) | RAD51CA12CA1CA2CA9 | |
| SCHEMBL8410035 | 0.89 | RAD51 (0.55) | RAD51CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613834-B1 | TREATMENT COMPOSITIONS COMPRISING LOW LEVELS OF AN OLIGOAMINE | PROCTER & GAMBLE (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250313777-A1 | TREATMENT COMPOSITIONS COMPRISING ETHOXYQUIN | PROCTER & GAMBLE COMPANY, THE | 2025-10-09 | — | — | US | disclosed |
| US-12195702-B2 | Treatment compositions comprising low levels of an oligoamine | THE PROCTER & GAMBLE COMPANY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20220177810-A1 | TREATMENT COMPOSITIONS COMPRISING LOW LEVELS OF AN OLIGOAMINE | PROCTER & GAMBLE (US) | 2022-06-09 | — | — | US | disclosed |
| US-11326129-B2 | Fabric care compositions that include a graft copolymer and related methods | THE PROCTER & GAMBLE COMPANY (US) | 2022-05-10 | — | — | US | disclosed |
| US-11279901-B2 | Treatment compositions comprising low levels of an oligoamine | THE PROCTER & GAMBLE COMPANY (US) | 2022-03-22 | — | — | US | disclosed |
| US-11274266-B2 | Treatment compositions comprising a surfactant system and an oligoamine | THE PROCTER & GAMBLE COMPANY (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2021067983-A1 | FABRIC CARE COMPOSITIONS THAT INCLUDE A COPOLYMER AND RELATED METHODS | THE PROCTER & GAMBLE COMPANY (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067984-A1 | FABRIC CARE COMPOSITIONS THAT INCLUDE A COPOLYMER AND RELATED METHODS | THE PROCTER & GAMBLE COMPANY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210095229-A1 | FABRIC CARE COMPOSITIONS THAT INCLUDE A COPOLYMER AND RELATED METHODS | THE PROCTER AND GAMBLE COMPANY | 2021-04-01 | — | — | US | disclosed |
| EP-3798289-A1 | FABRIC CARE COMPOSITIONS THAT INCLUDE A COPOLYMER AND RELATED METHODS | The Procter & Gamble Company (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3798288-A1 | FABRIC CARE COMPOSITIONS THAT INCLUDE A COPOLYMER AND RELATED METHODS | The Procter & Gamble Company (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20200063069-A1 | TREATMENT COMPOSITIONS COMPRISING A SURFACTANT SYSTEM AND AN OLIGOAMINE | THE PROCTER AND GAMBLE COMPANY | 2020-02-27 | — | — | US | disclosed |
| US-20200063068-A1 | TREATMENT COMPOSITIONS COMPRISING LOW LEVELS OF AN OLIGOAMINE | THE PROCTER AND GAMBLE COMPANY | 2020-02-27 | — | — | US | disclosed |
| EP-3613835-A1 | TREATMENT COMPOSITIONS COMPRISING A SURFACTANT SYSTEM AND AN OLIGOAMINE | The Procter & Gamble Company (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613834-A1 | TREATMENT COMPOSITIONS COMPRISING LOW LEVELS OF AN OLIGOAMINE | The Procter & Gamble Company (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-0550048-B2 | Inorganic ion exchange material and detergent composition | KAO CORP (JP) | 1999-07-28 | — | — | EP | disclosed |
| US-5427711-A | An ion exchanger comprising the oxide of sodium and/or potassium, calcium and/or magnesium, silicon; alkalinity, water insolubility | KAO CORPORATION (JP) | 1995-06-27 | — | — | US | disclosed |
| EP-0550048-A1 | Inorganic ion exchange material and detergent composition | Kao Corporation (JP) | 1993-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177810-A1 | TREATMENT COMPOSITIONS COMPRISING LOW LEVELS OF AN OLIGOAMINE | OAT, OTC, PHOSPHO1 | CA12 2755/4885CA1 3265/4885CA2 4354/4885 |
| US-12195702-B2 | Treatment compositions comprising low levels of an oligoamine | OAT, OTC, PHOSPHO1 | CA12 2755/4885CA1 3265/4885CA2 4354/4885 |
| US-20200063068-A1 | TREATMENT COMPOSITIONS COMPRISING LOW LEVELS OF AN OLIGOAMINE | OAT, OTC, PHOSPHO1 | CA12 2755/4885CA1 3265/4885CA2 4354/4885 |
| US-11279901-B2 | Treatment compositions comprising low levels of an oligoamine | OAT, OTC, PHOSPHO1 | CA12 2755/4885CA1 3265/4885CA2 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.